Inhibition of KLF5, the positive transcriptional regulator of cardiac Ppara, leads to cardiac dysfunction, and cardiomyocyte-specific ablation of KLF5 decreases cardiac ATP and FAO levels, leading to cardiac insufficiency. Here, KLF5 is linked to heart failure.